Gómez-Barreto D, Espinosa-Monteros LE, López-Enríquez C, Jiménez-Rojas V, Rodríguez-Suárez R

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 391-397
Archivo PDF: 0. Kb.

RESUMEN

Objetivo. Conocer la epidemiología de la enfermedad neumocócica invasora (ENI) en un hospital pediátrico y analizar los factores de riesgo relacionados con la mortalidad, la distribución de serotipos y el patrón de susceptibilidad de S. pneumoniae. Material y métodos. Revisión retrospectiva de los casos de ENI en un hospital pediátrico de tercer nivel, entre 1997 y 2004. Resultados. En 156 pacientes la mortalidad fue de 27.5%. Los serotipos de neumococo más frecuentemente relacionados con la mortalidad fueron: 14, 6B, 23F, 6A, 19F y 19A; no hubo relación de mortalidad con la resistencia a antibióticos. El 28.2% mostró resistencia a penicilina y 24.6% a cefotaxima. A través del modelo multivariado, se encontró una relación estadísticamente significativa entre la mortalidad y enfermedad previa (IC 95%; 2.5-18.3; p‹ 0.05). Conclusiones. La mortalidad asociada a la ENI tuvo relación significativa con antecedente de una enfermedad previa y con seis serotipos, cinco incluidos en la vacuna neumocócica conjugada 7-valente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Centers of Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mortal Wkly Rep 1997;46 (RR-8):1-24.

2. Centers of Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Inmunization Practices (ACIP). MMWR 2000;49 (RR-09):1-35.

3. Syriopoulou V, Daikos GL, Soulis K, et al. Epidemiology of invasive childhood pneumococcal infections in Greece. Acta Pediatr Suppl 2000;89:30-34.

4. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: followup at age 5 years. BMJ 2001;323:533-536.

5. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia, correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-237.

6. Levine OS, Farley M, Harrison LH, Lefkowitz L, McGeer A, Schuchat A. Risk factors for invasive pneumococcal disease in children: a population– based case-control study in North America. Pediatrics 1999;103:E28.

7. Rückinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 2009;28:118-122.

8. Turner RB, Lande AE, Chase P, Hilton N, Weinberg D. Pneumonia in Pediatrics outpatients: cause and clinical manifestations. J Pediatr 1987; 111:194-200.

9. Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type b era. Arch Pediatr Adolesc Med 1998; 152:624-628.

10. Castañeda E, Agudelo IC, Regueira M, Corso A, de Cueto Brandileone MC, et al. Laboratory–based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infec Dis J 2009;28;e265-e270.

11. Center for Disease Control and Prevention (CDC). Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 2008;57(42):1148-1151.

12. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: An update from the Centers for Disease Control and Prevention´s Pneumococcal Sentinel Surveillance System. J Infect Dis 1996; 174(5):986-993.

13. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis 2002;34:1613-1620.

14. Hortal M, Lovgren M, de la Hoz F, Agudelo CI, Brandileone MC, Camou T et al. Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries: 1993-1999. Surveillance Microb Drug Resist 2001;7: 391-401.

15. Eskola J, Black S, Shinefield H. Pneumococcal conjugated vaccines. In Plotkin SA, Orstein WA, eds. Vaccine 4th ed Philadelphia WB Saunders. 2004: 539-524.

16. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern Californi Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-195.

17. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl Med 2001;344:403-409.

18. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein- polysacharide conjugate vaccine. N Engl J Med 2003;348:1737-1746.

19. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A. et al. Effect of introduction of the pneumoccocal conjugate vaccine on drugresistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-1463.

20. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S08. Pennsylvania: CLSI, 2008;28(1).

21. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976;43:699-709.

22. Dagan R, Greenberg D, Jacobs M, Philips B. Pneumococcal infections. In Feigin, Cherry, Demmler-Harrison, Kaplan, eds. Textbook of pediatric infectious diseases. 6th ed. Philadelphia: WB Saunders, 2009:1288-1342.

23. Palacios T, Gamez J, Flores H. Desnutrición energético proteica en: Introducción a la pediatría. Chapter 14. 6th ed. Mexico: Méndez Editores, 1991: 131-142.

24. Scheifele D, Halperin S, Pelletier L, Talbot J. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory, Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis 2000;31:54-64.

25. Jacobs NM, Lerdkachornsuk S, Metzger WI. Pneumococcal bacteremia in infants and childreen: a ten year experience of the Cook County Hospital with special reference to the pneumococcal serotypes isolated. Pediatrics 1979; 64(3):296-300.

26. Ulloa–Gutierrez R, Avila-Aguero ML, Herrera ML, Herrera JF, Arguedas A. Invasive pneumococcal disease in Costa Rican children: a seven year survey. Pediatr Infect Dis J 2003;22:1069-1074.

27. Davison M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986- 1990: ethnic differences and opportunities for prevention. J Infect Dis 1994;170: 368-376.

28. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccine 2009;8:977-986.

29. Kertesz DA, DiFabio JL, de Cunto Brandileone MC, Castañeda E, Echániz-Avilez G, Heitmann I, et al. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study. Clin Infect Dis 1998;26:1355-1361.

30. Levine MM, Lagos R, Levine OS, Heitmann I, Enriquez N, Pinto ME, et al. Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J 1998;17(4):287-293.

31. Pneumococcal regional serotypes distribution for pneumococcal AMC TPP. [Available at: www. Vaccineaamc.org/filesTTP_ codebook.pdf]

32. Kaplan SL, Mason EO, Wald E, Tan TQ, Schutze GE, Bradley JS, et al. Six year multicenter surveillance of invasive pneumococcal infection in children. Pediatr Infect Dis J 2002;21(2):141-147.

33. Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J 2005;24(4):320-323.

34. Shapiro ED, Austrian R. Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut. J Infect Dis 1994;169:212-214.